Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Live Attenuated Leishmania donovani Centrin Gene–Deleted Parasites Induce IL-23–Dependent IL-17–Protective Immune Response against Visceral Leishmaniasis in a Murine Model
Saumyabrata Banerjee, Parna Bhattacharya, Pradeep K. Dagur, et al.
The Journal of Immunology (2017) Vol. 200, Iss. 1, pp. 163-176
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing
Wen‐Wei Zhang, Subir Karmakar, Sreenivas Gannavaram, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 106
Peptide Vaccines for Leishmaniasis
Rory Cristiane Fortes de Brito, Jamille Mirelle de Oliveira Cardoso, Levi Eduardo Soares Reis, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 85
Host–Pathogen Interaction in Leishmaniasis: Immune Response and Vaccination Strategies
Hadida Yasmin, Anureeta Adhikary, Mohammed N. Al‐Ahdal, et al.
Immuno (2022) Vol. 2, Iss. 1, pp. 218-254
Open Access | Times Cited: 40
LmCen−/− based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia
Thouraya Boussoffara, Imen Labidi, Malek Trimèche, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Vaccine candidates against leishmania under current research
Salvador Iborra, José Carlos Solana, José M. Requena, et al.
Expert Review of Vaccines (2018) Vol. 17, Iss. 4, pp. 323-334
Closed Access | Times Cited: 81
Characterization of a new Leishmania major strain for use in a controlled human infection model
Helen Ashwin, Jovana Sádlová, Barbora Vojtková, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 44
Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development
Greta Volpedo, Thalia Pacheco‐Fernández, Parna Bhattacharya, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 43
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection
Daniela P. Lage, Patrícia A.F. Ribeiro, Daniel Dias, et al.
npj Vaccines (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 43
Revival of Leishmanization and Leishmanin
Thalia Pacheco‐Fernández, Greta Volpedo, Sreenivas Gannavaram, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 39
The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates
Greta Volpedo, Parna Bhattacharya, Sreenivas Gannavaram, et al.
Pathogens (2022) Vol. 11, Iss. 4, pp. 431-431
Open Access | Times Cited: 27
Chimeric Vaccines Designed by Immunoinformatics-Activated Polyfunctional and Memory T Cells That Trigger Protection against Experimental Visceral Leishmaniasis
Rory Cristiane Fortes de Brito, Jerônimo Conceição Ruiz, Jamille Mirelle de Oliveira Cardoso, et al.
Vaccines (2020) Vol. 8, Iss. 2, pp. 252-252
Open Access | Times Cited: 33
Next-Generation Leishmanization: Revisiting Molecular Targets for Selecting Genetically Engineered Live-Attenuated Leishmania
Paulo Otávio Lourenço Moreira, Paula Monalisa Nogueira, Rubens Lima do Monte‐Neto
Microorganisms (2023) Vol. 11, Iss. 4, pp. 1043-1043
Open Access | Times Cited: 12
Toll-like Receptors and Inflammatory Cytokines in the Skin of Acanthamoeba spp. Infected Immunocompetent and Immunosuppressed Mice
Agnieszka Wojtkowiak‐Giera, Danuta Kosik-Bogacka, Natalia Łanocha-Arendarczyk, et al.
Experimental Parasitology (2025), pp. 108944-108944
Closed Access
Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis
Satish Chandra Pandey, Awanish Kumar, Mukesh Samant
Parasite Immunology (2020) Vol. 42, Iss. 9
Closed Access | Times Cited: 27
miR-21 Expression Determines the Early Vaccine Immunity Induced by LdCen−/− Immunization
Sreenivas Gannavaram, Parna Bhattacharya, Abid Siddiqui, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 23
Combination of Mycobacterium indicus pranii and Heat-Induced Promastigotes Cures Drug-Resistant Leishmania Infection: Critical Role of Interleukin-6-Producing Classical Dendritic Cells
Somaditya Dey, Debarati Mukherjee, Sirin Salma Sultana, et al.
Infection and Immunity (2020) Vol. 88, Iss. 6
Open Access | Times Cited: 21
Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis
Amrita Saha, Souravi Roy, Anindita Ukil
Infection and Immunity (2022) Vol. 90, Iss. 8
Open Access | Times Cited: 14
Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces
Priyanka H. Mazire, Bhaskar Saha, Amit Roy
International Immunopharmacology (2022) Vol. 110, pp. 108969-108969
Closed Access | Times Cited: 13
Growth arrested live-attenuated Leishmania infantum KHARON1 null mutants display cytokinesis defect and protective immunity in mice
Ana Maria Murta Santi, Juliane S. Lanza, Luiza Guimarães Tunes, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 21
Synthetic Peptides Elicit Strong Cellular Immunity in Visceral Leishmaniasis Natural Reservoir and Contribute to Long-Lasting Polyfunctional T-Cells in BALB/c Mice
Rory Cristiane Fortes de Brito, Jamille Mirelle de Oliveira Cardoso, Levi Eduardo Soares Reis, et al.
Vaccines (2019) Vol. 7, Iss. 4, pp. 162-162
Open Access | Times Cited: 20
Exploring the paradox of defense between host and Leishmania parasite
Diksha Kumari, Kuljit Singh
International Immunopharmacology (2021) Vol. 102, pp. 108400-108400
Closed Access | Times Cited: 17
Identifying Rab2 Protein as a Key Interactor of Centrin1 Essential for Leishmania donovani Growth
Roshanara, R. N. Tandon, Mirza Sarwar Baig, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 9, pp. 3273-3288
Closed Access | Times Cited: 2
Report of the Fifth Post-Kala-Azar Dermal Leishmaniasis Consortium Meeting, Colombo, Sri Lanka, 14–16 May 2018
Eduard E. Zijlstra, Amresh Kumar, Abhijit Sharma, et al.
Parasites & Vectors (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice
Deepak Goyal, Poonam Keshav, Sukhbir Kaur
Immunobiology (2021) Vol. 226, Iss. 2, pp. 152057-152057
Closed Access | Times Cited: 13
Vaccine Development for Human Leishmaniasis
Marianna de Carvalho Clímaco, Lucas Kraemer, Ricardo Toshio Fujiwara
Springer eBooks (2023), pp. 307-326
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top